1. Project Name: Workshop for freeze-dry asepsis powder of anti-tumor medicine
2. Undertaking Units: Nanjing Xian Sheng Dong Yuan Pharmaceutical Company Ltd.
3. Major Contents of the Project
Tartaric acid Changchun Ruibin is used to treat non-cellule lung cancer and galactophore cancer, which has a good effect but small side-effect, and has a wide clinic application in the market both abroad and home. Thanks to the complexity of its manufacturing technics, the medicine is rarely produced by domestic producers, while most of it depends on importing. Therefore, its market gap is huge. In order to accommodate the need of market and improve the its benefits, the company has decided to build a workshop for freeze-dry asepsis powder of anti-tumor medicine.
4. Prospective gross investment
(1) Gross investment capital of the project involves ￥45 million.
(2) Construction periods of the project are supposed to be three years.
(3) Prospective return rate of the project is 29%.
(4) Prospective investment reclaiming periods of the project are 4.2 years.
5. Advice for introduction cooperation
Technological cooperation or investment cooperation
6. Linkman: Ge Zongming
Corresponding address: Xinglong Road No.8, Economic Development Area, Pukou, Nanjing
Mail Code: 211800 
Tel: 025-58286999－777
Fax: 025-58285555
E-mail: gezongming@simcereoa.com